M Chao FRANZCR; D Bolton FRACS; D Lim Joon FRANZCR; Y Chan FRACS; N Lawrentschuk FRACS; H Ho B. App. Sc., M. App Sc; S Spencer Grad Dip App Sc; J Wasiak M.PH., PhD; M Guerrieri FRANZCR; D Ow MBBS; A Troy FRACS; T Pham FRACS; S Sengupta FRACS; A Tan FRACS; K McMillan FRACS; G Koufogiannis FRACS; F Foroudi FRANZCR; M Ng FRANZCR; V Khoo FRANZCR.

Conflict of interest: None.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Introduction

To examine the long-term outcomes of high dose rate brachytherapy boost (HDR-BT) combined with external beam radiotherapy (EBRT) for intermediate and high-risk prostate cancer patients.

Methods

Data from 95 patients who underwent combined EBRT (50.4 Gy) and HDR-BT to the prostate between 2010 and 2017 were retrospectively analysed. Biochemical progression free survival (bPFS), local recurrence free survival (LRFS), metastatic free survival (MFS) and overall survival (OS) were estimated using Kaplan–Meier method. Regression analysis was conducted to identify important predictors of outcomes.

Results

A total of 24 patients received an initial HDR-BT dose of 18 Gy in three fractions, with the remaining 71 patients receiving 16 Gy in two fractions as per departmental protocol changes. Most patients (88%) received androgen deprivation therapy. A transurethral resection of the prostate (TURP) was performed in 14 patients and hydrogel spacers (HS) were used in 30 patients. Median follow-up was 58 months. The 5-year bPFS, LRFS, MFS and OS were 92%, 100%, 92% and 88%. Univariate regression revealed no statistical association between patient characteristics and time to relapse (all P > 0.1). Late > grade 2 genitourinary (GU) toxicity was 6.3%. The use of HS or prior TURP had no impact on late GU toxicity. Late Grade 1 gastrointestinal (GI) toxicity was 5.3%.

Conclusion

The combined HDR-BT with EBRT resulted in excellent bPFS. The cumulative risk of late GU and GI toxicity was low and can be further improved with preventative strategies such as a pre-emptive TURP and/or HS insertion.

References

1Hannoun-Lévi JM. Brachytherapy for prostate cancer: present and future. Cancer Radiother 2017; 21: 469–72.
10.1016/j.canrad.2017.06.009
PubMed Web of Science® Google Scholar
2Stish BJ, Davis BJ, Mynderse LA, Deufel CL. Choo R Brachytherapy in the management of prostate cancer. Surg Oncol Clin N Am 2017; 26: 491–513.
10.1016/j.soc.2017.01.008
PubMed Web of Science® Google Scholar
3Skowronek J. Current status of brachytherapy in cancer treatment – short overview. J Contemp Brachytherapy 2017; 9: 581–9.
10.5114/jcb.2017.72607
PubMed Web of Science® Google Scholar
4Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options. J Contemp Brachytherapy 2013; 5: 33–41.
10.5114/jcb.2013.34342
PubMed Web of Science® Google Scholar
5Ong WL, Evans SM, Millar JL. Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy. J Med Imaging Radiat Oncol 2018; 62: 256–61.
10.1111/1754-9485.12699
PubMed Web of Science® Google Scholar
6Dutta SW, Alonso CE, Libby B, Showalter TN. Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. Exp Rev of Med Dev 2018; 15: 71–9.
10.1080/17434440.2018.1419058
CAS PubMed Web of Science® Google Scholar
7Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965–74.
10.1016/j.ijrobp.2006.04.029
PubMed Web of Science® Google Scholar
8Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology™. J Natl Compr Canc Netw 2016; 14: 19–30.
10.6004/jnccn.2016.0004
PubMed Web of Science® Google Scholar
9 JD Brierley, MK Gospodarowicz, C Wittekind (eds). The TNM Classification of Malignant Tumours, 8th edn. Wiley Blackwell, Oxford, 2017.
Google Scholar
10Falk AT, Demontoy S, Chamorey E et al. High-dose-rate brachytherapy boost for prostate cancer: comparison of three different fractionation schemes. Brachytherapy 2017; 16: 993–9.
10.1016/j.brachy.2017.06.013
PubMed Web of Science® Google Scholar
11Vigneault E, Mbodji K, Magnan S et al. High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes. Radiother Oncol 2017; 124: 49–55.
10.1016/j.radonc.2017.06.012
PubMed Web of Science® Google Scholar
12Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU Int 2017; 120: 56–60.
10.1111/bju.13659
CAS PubMed Web of Science® Google Scholar
13Bece A, Patanjali N, Jackson M, Whitaker M, Hruby G. High-dose-rate brachytherapy boost for prostate cancer: outcomes and genitourinary toxicity. Brachytherapy 2015; 14: 670–6.
10.1016/j.brachy.2015.04.004
PubMed Web of Science® Google Scholar
14Khor R, Duchesne G, Tai KH et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 85: 679–85.
10.1016/j.ijrobp.2012.07.006
PubMed Web of Science® Google Scholar
15Zaorsky NG, Doyle LA, Yamoah K et al. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev 2014; 40: 414–25.
10.1016/j.ctrv.2013.10.006
PubMed Web of Science® Google Scholar
16Thiruthaneeswaran N, Hoskin PJ. High dose rate brachytherapy for prostate cancer: standard of care and future direction. Cancer Radiother 2016; 20: 66–72.
10.1016/j.canrad.2016.01.001
CAS PubMed Web of Science® Google Scholar
17Morris WJ, Tyldesley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275–85.
10.1016/j.ijrobp.2016.11.026
PubMed Web of Science® Google Scholar
18Awad MA, Gaither TW, Baradaran N, Breyer BN, Osterberg EC. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2018; 21: 168–74.
10.1038/s41391-017-0028-3
PubMed Web of Science® Google Scholar
19Peddada AV, Jennings SB, Faricy PO, Walsh RA, White GA, Monroe AT. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 2007; 178: 1963–7.
10.1016/j.juro.2007.07.028
PubMed Web of Science® Google Scholar
20Olarte A, Cambeiro M, Moreno-Jimenez M et al. Dose escalation with external beam radiation therapy and high dose rate brachytherapy combined with long term androgen deprivation therapy in high and very high-risk prostate cancer: comparison of two consecutive high dose rate schemes. Brachytherapy 2016; 15: 127–35.
10.1016/j.brachy.2015.12.008
PubMed Web of Science® Google Scholar
21Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity and incontinence following transurethral resection of prostate after brachytherapy. J Urol 2005; 173: 808–12.
10.1097/01.ju.0000152698.20487.0e
CAS PubMed Web of Science® Google Scholar
22Ivanowicz A, Wakeman CM, Hubbard RT, DeVoe WB, Haake MR, Teigland CM. Two step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low to intermediate risk prostate cancer. Brachytherapy 2012; 11: 483–8.
10.1016/j.brachy.2011.08.006
PubMed Web of Science® Google Scholar
23Chao M, Spencer S, Guerrieri M et al. A single institution analysis of low dose rate brachytherapy: 5 year reported survival and late toxicity outcomes. J Contemp Brachytherapy 2018; 10: 155–61.
10.5114/jcb.2018.75600
PubMed Web of Science® Google Scholar
24Beydoun N, Bucci JA, Chin YS, Malouf D, Enari E, Painter SD. First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy. Brachytherapy 2013; 12: 368–74.
10.1016/j.brachy.2013.01.164
PubMed Web of Science® Google Scholar
25Yeh J, Lehrich B, Tran C et al. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 2016; 15: 283–7.
10.1016/j.brachy.2015.12.007
PubMed Web of Science® Google Scholar
26Orio PF 3rd, Nguyen PL, Buzurovic I, Cail DW, Chen YW. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys 2016; 96: 624–8.
10.1016/j.ijrobp.2016.07.013
PubMed Web of Science® Google Scholar

Citing Literature

Volume63, Issue3

June 2019

Pages 415-421

High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes

Abstract

Introduction

Methods

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes

Abstract

Introduction

Methods

Results

Conclusion

References

Citing Literature

References

Related

Information